Atul Pande, a director at Immunovant, Inc. (NASDAQ:IMVT), sold shares of the company’s common stock totaling $192,000 on May 20, 2026, following the exercise of stock options.
The transactions involved Mr. Pande acquiring 6,000 shares of common stock by exercising stock options at a price of $8.43 per share, amounting to $50,580. These options were fully vested. Both the acquisition and subsequent sale were executed pursuant to a Rule 10b5-1 trading plan, which Mr. Pande adopted on December 26, 2025.
Concurrently, Mr. Pande sold 6,000 shares of Immunovant common stock at a price of $32.00 per share, generating a total of $192,000 from the sale. Following these transactions, Mr. Pande directly holds 116,731 shares of Immunovant common stock and indirectly holds an additional 20,000 shares through a trust.
The insider sale comes as Immunovant shares have surged 147% over the past year and currently trade at $35.56, near their 52-week high of $36.28. According to Bond.az analysis, the stock appears overvalued relative to its Fair Value. The company, valued at $7.27 billion, remains unprofitable with negative earnings of $2.77 per share over the last twelve months.
In other recent news, Roivant Sciences reported its fourth-quarter earnings for fiscal year 2026, highlighting a strong cash position and strategic advancements in its product pipeline. The company, however, missed earnings per share expectations, reporting an EPS of -0.73 compared to the forecasted -0.6. Despite this, Roivant remains committed to its long-term growth strategy. Immunovant, a significant part of Roivant’s portfolio, had its stock rating reiterated as a Buy by Stifel, with a price target of $49.00. This follows the company’s fourth-quarter results and trial data from IMVT-1402 in rheumatoid arthritis. The trial’s open-label Part 1 portion showed absolute response rates above 70% on ACR20. The study focused on patients with inadequate response to two or more therapies and ACPA-positive status.
